Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM).
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 10 Jan 2017 Status changed from active, no longer recruiting to completed.
- 29 Oct 2013 New source identified and integrated (M.D. Anderson Cancer Center; SWOGS0722).
- 17 Apr 2013 Planned end date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.